Manta Pharma leverages patient-specific digital twins to model disease progression, integrating experimental and clinical multimodal data, including imaging, omics, and semantic data, combined with causal analysis for a comprehensive understanding
Identify responder biomarker signatures to optimize patient stratification and site selection for your clinical trials, even post-datalock.
Gain insights into the underlying mechanisms of action of your therapeutic assets, either as standalone treatments or in combination.
Expand your therapeutic portfolio by repositioning existing assets to address additional indications, or rescue stalled clinical programs with actionable insights.